TT
Tavira Therapeutics is developing a modular AAV capsid platform to enhance tissue-specific transgene delivery for gene therapy applications. This technology aims to improve the precision and efficacy of gene therapies by targeting specific tissues, thereby increasing therapeutic outcomes.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Tavira Therapeutics is developing a modular AAV capsid platform to enhance tissue-specific transgene delivery for gene therapy applications. This technology aims to improve the precision and efficacy of gene therapies by targeting specific tissues, thereby increasing therapeutic outcomes.